Hints and tips:
...Wockhardt was not the only Indian company targeted by US regulators over practices at their plants....
...Wockhardt has yet to report to the Bombay Stock Exchange on the likely impact of the ban, and its shares recovered slightly to be down 9 percent by mid-morning....
...Overseas regulators have been scrutinising and banning products from some of India’s biggest and most reputable groups — including Sun Pharmaceuticals, IPCA, and Wockhardt — many of which have ongoing relationships...
...It is also a major blow to Wockhardt....
...Khorakiwala, managing director of Wockhardt....
...Britain’s drug regulator recently ordered Wockhardt, an Indian generics producer, to recall some of its medicines due to concerns about manufacturing practices at one of its factories....
...Still, companies including Fame India, Wockhardt, Mastek and Heidelberg Cement fell as much as 9 per cent, 7 per cent, 8.5 per cent, and 5 per cent, respectively, in a flat Mumbai market after being added...
...Danone buys Wockhardt nutrition’s unit India’s Wockhardt has signed an agreement to sell its nutrition business to French dairy giant Danone for about EUR250m ($355m), the WSJ reports....
...Wockhardt is proving a bitter pill for foreign investors....
...Fortis opened its first hospital in 2001 in the agricultural heartland state of Punjab, and now owns 40 Indian hospitals, including 10 recently acquired from Wockhardt Hospitals in Bangalore, Calcutta and...
...Other companies that have suffered are those that borrowed in the form of foreign currency convertible bonds, like Wockhardt....
...Employees at a facility run by health group Wockhardt Hospitals have also gone on strike....
...“Wockhardt has a very good management,” said one person close to the deal....
...Ranbaxy follows Indian rivals Sun Pharma Advanced Research Company (Sparc), Orchid Research , Wockhardt, Glenmark Pharmaceuticals and Nicholas Piramal, each of which has a plan for drug development spin-offs...
...Several companies, including property developer Emaar MGF Land and hospital group Wockhardt, have shelved their planned market listings in India because of poor market conditions....
...Sentiment is so weak that last week, developer Emaar MGF Land, which is aiming to raise $1.6bn, was forced to slash its price range, and healthcare company Wockhardt Hospitals had to reduce the size of its...
...The first IPO to fail was Wockhardt Hospitals. The healthcare specialist’s $165m IPO never got off the ground, even though the offer period was extended....
...Indian rivals, such as Ranbaxy Laboratories and Wockhardt, have been quicker to seize the opening in Europe....
International Edition